Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.London Genetics, a provider of pharmacogenetics in clinical drug discovery and development, and Astrimmune, focused on gastrointestinal cancers, have entered into a collaboration to plan a biomarker identification programme.
Subscribe to our email newsletter
Under the terms of the collaboration, which is supported by a grant from the UK East Midlands Development Agency, London Genetics and Astrimmune will put together a proposal for identification of biomarkers predictive of clinical response.
Astrimmune’s vaccine candidate induces the production of antibodies against gastrin, a hormone which is known to stimulate the growth of many types of gastrointestinal cancer.
London Genetics CEO Dominique Kleyn said that this collaboration is a pharmacogenetics development opportunity, and they are pleased to be working with Astrimmune on this important project.
"As exemplified by our recent collaboration with Diaceutics and increasingly recognised by the biopharmaceutical industry, pharmacogenetics, biomarkers and patient stratification are becoming an important part of the drug discovery and development process," Kleyn said.